To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa™) in patients
with refractory non—small-cell lung cancer (NSCLC) treated in a community-based setting …

We present a series of cases that illustrate potential benefits of the targeted agent gefitinib
for patients with advanced and heavily pretreated non–small-cell lung cancer (NSCLC). In 2 …

Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …

7059 Background: Gefitinib is active for recurrent NSCLC after platinum-based
chemotherapy (Fukuoka M, et al. J Clin Oncol 21: 2237, 2003. Kris MG, et al. JAMA 290 …

Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …

Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment …

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …

Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …

Introduction: Gefitinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI) that demonstrated
efficacy in patients with advanced non-small cell lung cancer (NSCLC) across therapy lines …